ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.21 | $0 | -$475,000 |
| 2026 Q1 | -0.21 | $0 | -$438,000 |
| 2025 Q4 | -0.22 | $0 | -$854,000 |
| 2025 Q3 | -0.21 | $0 | $383,000 |
| 2025 Q2 | 0.11 | $1M | -$176,000 |
| 2025 Q1 | -0.62 | $0 | -$1M |
| 2024 Q4 | 4.54 | $0 | -$764,000 |
| 2024 Q3 | -1.92 | $0 | -$3M |